Other Clinical Trial - Investigator Sponsored Trial of Polypoidal

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04101604` - Biomarkers of Common Eye Diseases
Active, not recruiting	`NCT01950741` - Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy	Phase 4
Completed	`NCT01469156` - Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy	Phase 1/Phase 2
Recruiting	`NCT02597855` - Comparison of the Short-term Outcomes of Intravitreal Aflibercept Injection Between Two Subtypes of Polypoidal Choroidal Vasculopathy Using Indocyanine Green Angiography	N/A
Completed	`NCT02495181` - Randomized, Double-masked, Sham-controlled Phase 4 Study, Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy in Patients With Polypoidal Choroidal Vasculopathy	Phase 4
Active, not recruiting	`NCT02976194` - Intraocular Cytokine in Recurrence of Polypoidal Choroidal Vasculopathy	Phase 4
Recruiting	`NCT01248117` - Safety Study of High-Dose Ranibizumab for Polypoidal Choroidal Vasculopathy	Phase 1/Phase 2
Recruiting	`NCT04707027` - Interval of Disease Inactivity After Complete Polypoidal Regression in PCV Receiving Aflibercept	N/A
Recruiting	`NCT02141308` - OCT in Rare Chorioretinal Diseases
Completed	`NCT01871376` - Intravitreal Aflibercept Injection for Polypoidal Choroidal Vasculopathy With Hemorrhage or Exudation	Phase 4
Completed	`NCT00470977` - Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy	Phase 1/Phase 2
Recruiting	`NCT00383812` - Intravitreal Bevacizumab for Polypoidal Choroidal Vasculopathy	N/A
Completed	`NCT00837330` - Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy	Phase 1/Phase 2
Completed	`NCT05229237` - Conbercept for Polypoidal Choroidal Vasculopathy（START Study）
Not yet recruiting	`NCT04380974` - Efficacy and Safety of Two Regimens of Anti-VEGF Therapy in Chinese Patients With Polypoidal Choroidal Vasculopathy	Phase 4
Recruiting	`NCT02815176` - Angiographic Characteristics of CSC, PCV Patients and Thrombotic Bio-markers	N/A
Active, not recruiting	`NCT00344617` - Off-Label AVASTIN (BEVACIZUMAB) For Serosanguinous Maculopathy	Phase 3
Recruiting	`NCT03929731` - Long-term Outcomes, Recurrence Rates, and Treatment Needs in Polypoidal Choroidal Vasculopathy (PCV)
Completed	`NCT01023295` - Study Evaluating the Safety and Response of Fosbretabulin in Asian Patients With Polypoidal Choroidal Vasculopathy (PCV)	Phase 2
Completed	`NCT02821520` - Initial Versus Delayed PDT Combination With Conbercept in PCV	Phase 4

NCT number	NCT01884597
Study type	Interventional
Source	Hawaii Pacific Health
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	November 2010
Completion date	August 2014

Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab Prospectively (PEARL2) — PEARL2

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms